OREANDA-NEWS. April 19, 2016. IONA™ - Up, running and available on the NHS:  Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA estimates the risk that a fetus has any of Down's, Edwards' or Patau's syndromes caused by a genetic abnormality.

Although IONA is entering a competitive and litigious market, it has some advantages, is CE Marked and is the first to win a UK NHS contract. Premaitha is subject to distracting IP infringement claims but 1H'16 results showed early signs of commercial traction which are expected to accelerate herein.

Also, Premaitha has signed a strategically important partnership with Thermo Fisher which adds considerable credibility.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/premaitha-health-plc-documents/nipt-initiation-note---28-jan-2016